Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
IPO Year: 2016
Exchange: NASDAQ
Website: reatapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/6/2023 | $140.00 | Outperform | TD Cowen |
| 6/12/2023 | $80.00 → $115.00 | Market Perform → Outperform | SVB Securities |
| 10/19/2022 | $75.00 | Buy | Guggenheim |
| 3/24/2022 | $91.00 | Buy | Goldman |
| 3/1/2022 | $39.00 → $34.00 | Neutral | Goldman Sachs |
| 12/9/2021 | $39.00 | Buy → Neutral | Goldman Sachs |
| 12/9/2021 | $110.00 → $37.00 | Outperform → Neutral | Robert W. Baird |
| 12/9/2021 | $112.00 → $68.00 | Overweight | Cantor Fitzgerald |
| 12/9/2021 | $180.00 → $43.00 | Overweight | Barclays |
| 12/9/2021 | $282.00 → $35.00 | Outperform → Market Perform | SVB Leerink |
TD Cowen initiated coverage of Reata Pharmaceuticals with a rating of Outperform and set a new price target of $140.00
SVB Securities upgraded Reata Pharmaceuticals from Market Perform to Outperform and set a new price target of $115.00 from $80.00 previously
Guggenheim initiated coverage of Reata Pharmaceuticals with a rating of Buy and set a new price target of $75.00
Goldman resumed coverage of Reata Pharmaceuticals with a rating of Buy and set a new price target of $91.00
Goldman Sachs reiterated coverage of Reata Pharmaceuticals with a rating of Neutral and set a new price target of $34.00 from $39.00 previously
Goldman Sachs downgraded Reata Pharmaceuticals from Buy to Neutral and set a new price target of $39.00
Robert W. Baird downgraded Reata Pharmaceuticals from Outperform to Neutral and set a new price target of $37.00 from $110.00 previously
Cantor Fitzgerald reiterated coverage of Reata Pharmaceuticals with a rating of Overweight and set a new price target of $68.00 from $112.00 previously
Barclays reiterated coverage of Reata Pharmaceuticals with a rating of Overweight and set a new price target of $43.00 from $180.00 previously
SVB Leerink downgraded Reata Pharmaceuticals from Outperform to Market Perform and set a new price target of $35.00 from $282.00 previously
Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company's previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen"). Approximately 99.65 percent of the votes cast by the Company's Class A common stockholders and Class B common stockholders, voting as a single class, entitled to vote at the special meeting, voted to approve the Merger, which represen
NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote. If you are an EQRX investor, and would like additional information abo
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ:RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to a
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that the United States Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) to update the drug substance specification for SKYCLARYS® (omaveloxolone), the first and only FDA approved drug for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. With the approval of the PAS, SKYCLARYS is now available to patients with Friedreich's ataxia in the United States. About SKYCLARYS® (omaveloxolone) SKYCLA
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced today that the U.S. Food and Drug Administration (FDA) accepted for filing the Prior Approval Supplement (PAS) to update the drug substance specification for SKYCLARYS® (omaveloxolone). As per the US Code of Federal Regulation, the filing means FDA has made a threshold determination that the PAS is sufficiently complete to permit a substantive review. As previously communicated, the PAS is being reviewed under expedited Priority Review with a target action date of mi
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company's research and development functions. "The team and I are excited to welcome Rajiv to Reata. His previous experience and his proven track record will help position the company for future growth," said Warren Huff, Chief Executive Officer. "His le
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that management will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 12 – 15, 2023, in Dana Point, California. Manmeet Soni, Reata's President, Chief Operating Officer, and Chief Financial Officer will be participating in a fireside chat during the conference. About Reata Reata is a biopharmaceutical company committed to developing and commercializing novel therapeutics for patients with serious or life-threatening diseases with
SKYCLARYS® Approved by FDA in the U.S. Approximately 500 Patient Start Forms Received for SKYCLARYS Marketing Authorization Application for Omaveloxolone in Europe Under Review Announced $275 Million Debt Facility and Extended Cash Guidance Through the End of 2026 Focus on Neurology Pipeline; Announced Discontinuation of Bardoxolone CKD Programs Conference Call with Management on May 10, 2023, at 8:30 a.m. ET Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, today announced financial results for the first quarter
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, today announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company's business operations and clinical development programs on May 10, 2023, before the U.S. financial markets open. Conference Call Information Reata's management will host a conference call on May 10, 2023, at 8:30 am ET. The conference call will be accessible by dialing (833) 470-1428 (toll-free domestic) or (929) 526-1599 (international)
Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ:RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to a
SKYCLARYS® Approved by FDA in the U.S. Approximately 500 Patient Start Forms Received for SKYCLARYS Marketing Authorization Application for Omaveloxolone in Europe Under Review Announced $275 Million Debt Facility and Extended Cash Guidance Through the End of 2026 Focus on Neurology Pipeline; Announced Discontinuation of Bardoxolone CKD Programs Conference Call with Management on May 10, 2023, at 8:30 a.m. ET Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, today announced financial results for the first quarter
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, today announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company's business operations and clinical development programs on May 10, 2023, before the U.S. financial markets open. Conference Call Information Reata's management will host a conference call on May 10, 2023, at 8:30 am ET. The conference call will be accessible by dialing (833) 470-1428 (toll-free domestic) or (929) 526-1599 (international)
FRIEDREICH'S ATAXIA IS AN ULTRA-RARE, PROGRESSIVE, NEUROMUSCULAR DISEASE THAT AFFECTS APPROXIMATELY 5,000 DIAGNOSED PATIENTS IN THE UNITED STATES SKYCLARYS IS INDICATED FOR THE TREATMENT OF FRIEDREICH'S ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER GRANTED MANAGEMENT TO HOST CONFERENCE CALL TODAY, FEBRUARY 28, 2023, AT 6:00 PM ET Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that the U.S. Food and Drug Administration ("FDA") has approved SKYCLARYS™ (omavelox
NDA for Omaveloxolone for Patients With Friedreich's Ataxia Under Review With PDUFA Date of February 28, 2023 FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the Omaveloxolone NDA and the Late Cycle Meeting Has Been Completed Provides Update on Commercial Preparation Conference Call With Management on November 8, 2022, at 8:30 A.M. ET Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter of 2022 and provided an update on the Company's business operations and clinical development programs. Recent Company Highlights Omaveloxolone in P
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the third quarter ended September 30, 2022, and provide an update on the Company's business operations and clinical development programs on November 8, 2022, before the U.S. financial markets open. Conference Call Information Reata's management will host a conference call on November 8, 2022, at 8:30 am ET. The conference call will be accessible by dialing (844) 200-6205 (toll-free domestic) or (929) 526-1599 (international) using access code 756839. The webcast link is https://events.q4inc.com/atten
Received Priority Review and Acceptance for Filing of the NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia Provides Update from FDA Mid-Cycle Communication Meeting on Omaveloxolone for Patients with Friedreich's Ataxia Announces Results of New Data and Analyses Submitted to FDA Conference Call With Management on August 8, 2022, at 8:30 a.m. ET Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter of 2022 and provided an update on the Company's business operations and clinical development programs. Recent Company Highlights Oma
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the second quarter ended June 30, 2022, and provide an update on the Company's business operations and clinical development programs on August 8, 2022, before the U.S. financial markets open. Conference Call Information Reata's management will host a conference call on August 8, 2022, at 8:30 am ET. The conference call will be accessible by dialing (844) 200-6205 (toll-free domestic) or (929) 526-1599 (international) using access code 964090. The webcast link is https://event.choruscall.com/mediafram
Completed Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia; Actively Preparing for Commercial Launch Updates Outcome of Type A Meeting with the FDA on the Protocol Amendment for FALCON Reaffirms Cash Runway Through end of 2024 Conference Call with Management on May 10, 2022, at 8:30 a.m. ET Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter of 2022 and provided an update on the Company's business operations and clinical development programs. "We are pleased to have recently completed rolling submission o
Submission status for REATA PHARMACEUTICALS INC's drug SKYCLARYS (ORIG-1) with active ingredient OMAVELOXOLONE has changed to 'Approval' on 02/28/2023. Application Category: NDA, Application Number: 216718, Application Classification: Type 1 - New Molecular Entity
15-12G - REATA PHARMACEUTICALS INC (0001358762) (Filer)
8-K - REATA PHARMACEUTICALS INC (0001358762) (Filer)
POSASR - REATA PHARMACEUTICALS INC (0001358762) (Filer)
S-8 POS - REATA PHARMACEUTICALS INC (0001358762) (Filer)
S-8 POS - REATA PHARMACEUTICALS INC (0001358762) (Filer)
S-8 POS - REATA PHARMACEUTICALS INC (0001358762) (Filer)
S-8 POS - REATA PHARMACEUTICALS INC (0001358762) (Filer)
S-8 POS - REATA PHARMACEUTICALS INC (0001358762) (Filer)
S-8 POS - REATA PHARMACEUTICALS INC (0001358762) (Filer)
S-8 POS - REATA PHARMACEUTICALS INC (0001358762) (Filer)
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company's research and development functions. "The team and I are excited to welcome Rajiv to Reata. His previous experience and his proven track record will help position the company for future growth," said Warren Huff, Chief Executive Officer. "His le
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. "We are thrilled to welcome Dr. Ryder to Reata's board," said Warren Huff, Reata's Chief Executive Officer. "He is joining us at a critical point in Reata's development with our New Drug Application under review with the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich's ataxia. His knowledge will be invaluable to help us achieve our mission in developing innovative therapies that change patients' lives for the bett
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13D - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13G - REATA PHARMACEUTICALS INC (0001358762) (Subject)
SC 13G/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)